News

Dr. Josep Maria Ribera
04/25/2017

A Josep Carreras Institute research team reveals the effectiveness of a new treatment for acute lymphoblastic leukaemia

•  A Josep Carreras Leukaemia Research Institute (IJC) acute lymphoblastic leukaemia (ALL) research team, led by Dr. Josep Maria Ribera, has participated in a study published in the prestigious journal, The New England Journal of Medicine.

• The study shows that treatment with blinatumomab significantly prolongs the life expectancy of adult patients with certain kinds of leukaemia, in comparison with standard treatment with chemotherapy.

•  This discovery is an important step forward for improving the prognosis for adult ALL patients, a kind of leukaemia with an incidence of 30 new cases per million every year in Spain.

More
04/19/2017

New therapeutic target for acute myeloid leukaemia found by Josep Carreras Institute research team

• The Josep Carreras Leukaemia Research Institute's (IJC) acute myeloid leukaemia research group, directed by Dr. Ruth M. Risueño, has published a paper in the prestigious journal Leukemia, considered to be the most important journal in the field of hematology.

• The study, the main author of which is Amaia Etxabe, has identified the importance of the serotonin receptor type 1 (HTR1) for therapy in acute myeloid leukaemia (AML).

• Acute myeloid leukaemia (AML) is the most common leukaemia in adults and accounts for 40% of all leukaemias in the western world. It is estimated that every year there are 15 new cases per million in our country. 

More
Webpage updated 10/16/2019 13:23:15